Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) (FAST2)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Primary Outcome Measures:
The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase. H0: λ icatibant/λ tranexamic acid =1 versus H1: λ icatibant/λ tranexamic acid ≠1 Where: λ icatibant refers to the hazard rate under icatibant and λ tranexamic acid refers to the hazard rate under tranexamic acid.
Secondary Outcome Measures:
- Additional efficacy assessments (Time to Almost Complete Symptom Relief)
- Safety and tolerability
- Pharmacoeconomics
| Condition | Intervention | Phase |
|---|---|---|
|
Hereditary Angioedema |
Drug: Icatibant Drug: Tranexamic Acid Drug: Oral Placebo Drug: S.C. Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Randomised Double Blind, Controlled, Parallel Group, Multicentre Study of a Subcutaneous Formulation of Icatibant Versus Oral Tranexamic Acid for the Treatment of Hereditary Angioedema (HAE) |
- Time to Onset of Symptom Relief. [ Time Frame: 2 days ] [ Designated as safety issue: No ]
The primary efficacy endpoint was Time to onset of symptom relief (TOSR) following treatment with either icatibant or tranexamic acid. The median time to onset of symptom relief for the icatibant group was compared to the the median time to onset of symptom relief for the tranexamic acid group.
TOSR was defined as the time between time of injection to time of first documented onset of symptom relief for the three primary symptoms: cutaneous swelling, cutaneous skin, and abdominal pain.
The primary symptom was based on the type of attack. For abdominal attacks, the single primary symptom was abdominal pain. For cutaneous attacks, the single primary symptom was either skin swelling or skin pain, whichever was most severe.
- Time to Almost Complete Symptom Relief [ Time Frame: 48 hours ] [ Designated as safety issue: No ]Almost complete symptom relief was defined as a score between 0 and 10 mm on the VAS for at least three consecutive measurements for all symptoms.
| Enrollment: | 85 |
| Study Start Date: | March 2005 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Randomized controlled -Icatibant
Subjects received S.C icatibant+ oral placebo Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL) Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart |
Drug: Icatibant
Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Other Name: Brand name, Firazyr®
Drug: Oral Placebo
hard capsule matched to tranexamic acid
Other Name: Placebo
|
|
Active Comparator: Randomized controlled-Tranexamic acid
Subjects received oral Tranexamic acid+ S.C. placebo Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region |
Drug: Tranexamic Acid
over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
Drug: S.C. Placebo
solution for injection, matched to icatibant for injection
Other Name: Placebo
|
|
Experimental: Controlled Open-label / laryngeal attack
Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
|
Drug: Icatibant
Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Other Name: Brand name, Firazyr®
|
|
Experimental: Untreated patients at the baseline
Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
|
Drug: Icatibant
Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
Other Name: Brand name, Firazyr®
|
Detailed Description:
This was a Phase III, randomised, double blind, double dummy, multicentre, controlled,parallel group study of a 30 mg s.c. formulation of icatibant for the treatment of patients with moderate to very severe symptoms of cutaneous and/or abdominal symptoms of HAE.
The study consisted of two parts: controlled phase and OLE phase. For the primary endpoint, Efficacy was determined by evaluating the differences in study outcomes using a Visual Analogue Scale for patients treated with icatibant and tranexamic acid.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age above 18 years;
- Documented diagnosis of HAE Type I or II (confirmed C1-INH deficiency);
- Current edema in the cutaneous, abdominal and/or laryngeal areas;
- Current edema moderate to severe according to the investigator's Symptom Score.
Exclusion Criteria:
- Diagnosis of angioedema other than HAE,
- Participation in a clinical trial of another investigational medicinal product (IMP)within the past month
- Treatment with any pain medication since onset of the current angioedema attack
- Treatment with replacement therapy, including C1-INH products, less than 3 days before onset of the current angioedema attack
- Treatment with Tranexamic acid replacement therapy within a week before onset of the current angioedema attack
- Treatment with ACE inhibitors
- Contraindications for Tranexamic acid
- Evidence of coronary artery disease based on medical history or Screening examination in particular unstable angina pectoris or severe coronary heart disease
- Congestive heart failure (class 3 and 4)
- Serum creatinine level of ≥ 250 μmol/L
- Serious concomitant illness that the investigator considered to be a contraindication for participation in the trial
- Pregnancy (as assessed prior to treatment) and/or breast-feeding
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00500656
| Italy | |
| Università degli Studi di Milano, Dipartimento di Medicina Interna | |
| Milano, Italy, 20123 | |
| Principal Investigator: | Marco Cicardi, Prof. Dr. | University of Milan |
More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Shire |
| ClinicalTrials.gov Identifier: | NCT00500656 History of Changes |
| Other Study ID Numbers: | JE049 #2102, 2004-001540-71 |
| Study First Received: | July 12, 2007 |
| Results First Received: | October 30, 2013 |
| Last Updated: | January 29, 2015 |
| Health Authority: | United States: Food and Drug Administration European Union: European Medicines Agency |
Additional relevant MeSH terms:
|
Angioedema Angioedemas, Hereditary Cardiovascular Diseases Genetic Diseases, Inborn Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Skin Diseases Skin Diseases, Vascular Urticaria Vascular Diseases Icatibant Tranexamic Acid Adrenergic Agents Adrenergic Antagonists |
Adrenergic beta-Antagonists Analgesics Analgesics, Non-Narcotic Anti-Inflammatory Agents Anti-Inflammatory Agents, Non-Steroidal Antifibrinolytic Agents Antirheumatic Agents Central Nervous System Agents Coagulants Fibrin Modulating Agents Hematologic Agents Hemostatics Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on March 01, 2015